GOLDEN, Colo., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the launch of a series of products for use in the development of advanced treatment of injury and diseases of joints. The new products are chondrocytes derived from human adult stem cells, mesenchymal stem cells (MSCs).  These cells produce collagen and are critical to proper joint function.  Joint disease and injury often involve defects in collagen production and/or damage to chondrocytes due to inflammation, disease or injury. The new products include native and fluorescent labeled MSC-derived human chondrocytes together with SPIO-labeled chondrocytes.  The later cells are labeled with super paramagnetic iron oxide (SPIO) and may be used for in-vivo imaging of chondrocytes using MRI (magnetic resonance imaging) a common clinical imaging procedure. The availability of native and multiply-labeled chondrocytes provides customers with numerous options to conduct in-vitro high throughput screening cell assays and to coordinate these studies with in-vivo studies.

Pete Shuster, CEO of Neuromics, said, "We are pleased to add Vitro Biopharma's MSC-derived chondrocytes to our expanding line of cells for use in cell-based assays.  We see a continual need for these products to fuel accelerating research by pharmaceutical and biotechnology firms to expand product pipelines.  The promise of stem cell-based regenerative medicine is also supported by stem cell-derived products suitable for in-vivo imaging that may be then correlated with clinical measurements of efficacy."

Dr. Jim Musick, Vitro Biopharma's President & CEO, said, "We are pleased to announce commercial availability of our MSC-derived human chondrocytes. These products offer numerous competitive advantages including consistent and well-defined cellular characteristics, multiple forms including native, fluorescent and SPIO-labeled that are suitable for numerous applications in current drug development, discovery and toxicology together with applications in joint regeneration research.   There are several debilitating joint diseases such as arthritis, osteoarthritis together with common injury to joints in both humans and animals.  We intend to support the development of new, modern treatments of these conditions with these products.  We plan further extensions of these products including clinical products and additional stem cell derived cells for use in drug discovery and development together with animal cells.  We are presently developing MSC-derived endothelial cells and osteoblasts for use in the development of advanced treatments of cardiovascular and orthopedic diseases."

About Neuromics, Inc.

Neuromics (, located in Minneapolis, MN, is a profitable and growing bio-reagents company. The company was initially built by supplying bio-markers to Neuroscience Researchers. Today, Neuromics provides a range of solutions that include markers, growth factors, gene expression analysis tools, apoptosis detection kits, primary cells and related media. These solutions are increasingly being used in combinations by customers to help accelerate or improve the process of drug discovery.

About Vitro Biopharma

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCQB: VODG;, owns US patents for production of FSH, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes.  In 2011, Vitro out-licensed its intellectual property related to treatment of infertility to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies.  Vitro also owns a pending US patent for generation of pluripotent stem cells and an additional pending patent for methods of mesenchymal stem cell (MSC) generation and related materials. Vitro's mission is "Harnessing the Power of Cells™" for the advancement of regenerative medicine to its full potential. Vitro operates within a modern biotechnology manufacturing, R&D and corporate facility in Golden, Colorado.  Vitro manufactures and sells "Tools for Stem Cell and Drug Development™", including human mesenchymal stem cells and derivatives, the MSC-Gro™ Brand of optimized media for stem cell self-renewal and lineage-specific differentiation.  Vitro formed a strategic alliance with HemoGenix®, Inc. ( to jointly manufacture and distribute the LUMENESC™ quantitative assay for determination of MSC quality, potency and response to toxic agents.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.  Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission.  Most of these factors are outside the control of the Company.  Investors are cautioned not to put undue reliance on forward-looking statements.  Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3

This information was brought to you by Cision,c9315310